NEW YORK (GenomeWeb News) – Nanogen today said it will market point-of-care tests for drugs of abuse made by American Bio Medica into the "hospital-related" setting.
 
Nanogen will re-brand the tests under its Tox STATus name and sell them using its existing sales force and distribution network. American Bio Medica will continue to sell the tests under their original brand to its core criminal justice and workplace markets, a spokesperson for the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.